Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Spotlight on medicines: Dronedarone

Medicines used to treat atrial fibrillation can cause various side effects. Dronedarone, the most recent antiarrhythmic drug to become available, is well tolerated. This article looks at its place in therapy

By Gemma Robinson and Sotiris Antoniou

Sinus rhythm



Antiarrhythmic treatment options for patients with atrial fibrillation are limited and an antiarrhythmic drug that can control symptoms with improved tolerability over amiodarone is a welcome addition.

Dronedarone, however, has limited ability to cardiovert patients to sinus rhythm and should be reserved for the maintenance of sinus rhythm in patients who have previously been cardioverted and for the control of ventricular rate.

Because dronedarone is not proarrhythmic and it also lacks the non-cardiac side effects seen with other antiarrhythmics, it is an attractive second-line option in certain pre-specified patient groups.

Full text article available to read as a PDF (1.3 MB) file.

Gemma Robinson is specialist cardiac pharmacist and Sotiris Antoniou is principal cardiac pharmacist, both at Barts and The London NHS Trust.


Citation: Clinical Pharmacist URI: 11027205

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary information

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.